Page 69 - 《中国药房》2025年6期
P. 69

综上所述,敲低 LncRNA MALAT1 可以抑制 OS 细                    (12):4500.
          胞的 DOX 耐药性,其机制可能是通过靶向 miR-154-5p/                  [12]  LIN C S,MIAO J F,HE J L,et al. The regulatory mecha‐
          CCND1轴实现的。然而,本研究局限于细胞实验,后续                              nism  of  LncRNA-mediated  ceRNA  network  in  osteosar‐
          将增加动物实验进行深入研究。                                          coma[J]. Sci Rep,2022,12(1):8756.
          参考文献                                               [13]  YANG F,WANG M,SHI J L,et al. LncRNA MALAT1
          [ 1 ]  WANG  X,ZHOU  T  J,YANG  X,et  al.  DDRGK1  en‐  regulates the proliferation,apoptosis,migration,and inva‐
                                                                  sion  of  osteosarcoma  cells  by  targeting  miR-873-5p/
              hances  osteosarcoma  chemoresistance  via  inhibiting
                                                                  ROCK1[J]. Crit Rev Eukaryot Gene Expr,2023,33(2):
              KEAP1-mediated  NRF2  ubiquitination[J].  Adv  Sci
              (Weinh),2023,10(14):e2204438.                       67-79.
                                                             [14]  LI F J,CHEN X,SHANG C,et al. Bone marrow mesen‐
          [ 2 ]  GUAN H P,XU H,CHEN J S,et al. Circ_0001721 en‐
              hances  doxorubicin  resistance  and  promotes  tumorige-  chymal  stem  cells-derived  extracellular  vesicles  promote
              nesis in osteosarcoma through miR-758/TCF4 axis[J]. Can‐  proliferation,invasion  and  migration  of  osteosarcoma
              cer Cell Int,2021,21(1):336.                        cells  via  the  LncRNA  MALAT1/miR-143/NRSN2/Wnt/
          [ 3 ]  叶天宝,张振宇,王伯仁,等. 多柔比星对人骨肉瘤细胞                       β-catenin axis[J]. Onco Targets Ther,2021,14:737-749.
              P-糖蛋白表达的影响[J]. 锦州医科大学学报,2022,43                [15]  范金柱,从飞,张文韬,等 . Circ_0001461 靶向抑制 miR-
              (3):53-56.                                          30a-5p对骨肉瘤细胞增殖和凋亡的影响[J]. 现代生物医
              YE T B,ZHANG Z Y,WANG B R,et al. Effect of doxo‐    学进展,2022,22(8):1413-1418.
              rubicin  on  P-glycoprotein  expression  in  human  osteosar‐  FAN J Z,CONG F,ZHANG W T,et al. The effect of circ_
              coma cells[J]. J Jinzhou Med Univ,2022,43(3):53-56.  0001461 targeting inhibition of miR-30a-5p on the proli-
          [ 4 ]  WAN  D  Q,QU  Y,ZHANG  L,et  al.  The  LncRNA    feration and apoptosis of osteosarcoma cells[J]. Prog Mod
              LINC00691  functions  as  a  ceRNA  for  miRNA-1256  to   Biomed,2022,22(8):1413-1418.
              suppress osteosarcoma by regulating the expression of ST5  [16]  TIAN  Q,GU  Y  F,WANG  F  F,et  al.  Upregulation  of
              [J]. Onco Targets Ther,2020,13:13171-13181.         miRNA-154-5p  prevents  the  tumorigenesis  of  osteosar‐
          [ 5 ]  LIU J X,SHANG G N. The roles of noncoding RNAs in   coma[J]. Biomed Pharmacother,2020,124:109884.
              the development of osteosarcoma stem cells and potential   [17]  ZHOU J H,XU L,YANG P,et al. Circ-ATAD1 is overex‐
              therapeutic  targets[J].  Front  Cell  Dev  Biol,2022,10:  pressed in osteosarcoma(OS)and suppresses the matura‐
              773038.                                             tion of miR-154-5p to increase cell invasion and migration
          [ 6 ]  YUE X,WU W Y,DONG M,et al. LncRNA MALAT1         [J]. J Orthop Surg Res,2021,16(1):699.
              promotes breast cancer progression and doxorubicin resis‐  [18]  VALLA M,KLÆSTAD E,YTTERHUS B,et al. CCND1
              tance  via  regulating  miR-570-3p[J].  Biomed  J,2021,44   amplification in breast cancer-associations with prolifera‐
              (6 Suppl. 2):S296-S304.                             tion,histopathological grade,molecular subtype and prog‐
          [ 7 ]  FEI D,YUAN H P,ZHAO M M,et al. LncRNA FGD5-      nosis[J]. J Mammary Gland Biol Neoplasia,2022,27(1):
              AS1  potentiates  autophagy-associated  doxorubicin  resis‐  67-77.
              tance by regulating the miR-154-5p/WNT5A axis in osteo‐  [19]  XIN C F,LU S T,LI Y,et al. miR-671-5p inhibits tumor
              sarcoma[J]. Cell Biol Int,2022,46(11):1937-1946.    proliferation  by  blocking  cell  cycle  in  osteosarcoma[J].
          [ 8 ]  NICULESCU Ş A,GRECU D C,SIMIONESCU C E,et al.    DNA Cell Biol,2019,38(9):996-1004.
              Immunoexpression of Ki67,p53 and cyclin D1 in osteo‐  [20]  YANG G,HE F,DUAN H,et al. LncRNA FLVCR-AS1
              sarcomas[J].  Rom  J  Morphol  Embryol,2021,62(3):  promotes  osteosarcoma  growth  by  targeting  miR381-3p/
              743-750.                                            CCND1[J]. Onco Targets Ther,2020,13:163-172.
          [ 9 ]  SHOAIB Z,FAN T M,IRUDAYARAJ J M K. Osteosar‐  [21]  LI  Z,TIAN  J  M,CHU Y,et  al.  Long  non-coding  RNA
              coma  mechanobiology  and  therapeutic  targets[J].  Br  J   PVT1(PVT1)affects the expression of CCND1 and pro‐
              Pharmacol,2022,179(2):201-217.                      motes  doxorubicin  resistance  in  osteosarcoma  cells[J].  J
          [10]  LI  R,RUAN  Q,ZHENG  J,et  al.  LINC01116  promotes   Bone Oncol,2023,43:100512.
              doxorubicin  resistance  in  osteosarcoma  by  epigenetically   [22]  WU J P,WANG C G,DING H Y. LncRNA MALAT1 pro‐
              silencing  miR-424-5p  and  inducing  epithelial-mesenchymal   motes neuropathic pain progression through the miR-154-
              transition[J]. Front Pharmacol,2021,12:632206.      5p/AQP9 axis in CCI rat models[J]. Mol Med Rep,2020,
          [11]  GODEL M,MORENA D,ANANTHANARAYANAN P,              21(1):291-303.
              et al. Small nucleolar RNAs determine resistance to doxo‐     (收稿日期:2024-09-27  修回日期:2025-02-18)
              rubicin in human osteosarcoma[J]. Int J Mol Sci,2020,21                             (编辑:舒安琴)








          中国药房  2025年第36卷第6期                                                 China Pharmacy  2025 Vol. 36  No. 6    · 703 ·
   64   65   66   67   68   69   70   71   72   73   74